Quick Answer
Cartesian Therapeutics, Inc. reported Net Income of -$130.30 million for fiscal year 2025.
Cartesian Therapeutics, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$130.30M | -68.3% |
| 2024 | -$77.42M | +64.8% |
| 2023 | -$219.71M | -721.0% |
| 2022 | $35.38M | +237.7% |
| 2021 | -$25.69M | +62.7% |
| 2020 | -$68.88M | -24.4% |
| 2019 | -$55.35M | +15.3% |
| 2018 | -$65.34M | -0.0% |
| 2017 | -$65.32M | -80.4% |
| 2016 | -$36.21M | -43.8% |
| 2015 | -$25.17M | -95.5% |
| 2014 | -$12.88M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$35.90M | -48.5% | -326.0% |
| June 30, 2025 | $15.89M | +14.8% | +189.7% |
| March 31, 2025 | -$17.71M | +68.8% | +26.8% |
| September 30, 2024 | -$24.18M | -168.6% | -274.8% |
| June 30, 2024 | $13.84M | +221.5% | +124.3% |
| March 31, 2024 | -$56.82M | -162.3% | -531.2% |
| September 30, 2023 | -$9.00M | -14.1% | +20.9% |
| June 30, 2023 | -$11.39M | -232.4% | +47.4% |
- Cartesian Therapeutics, Inc. showed a decrease of -68.3% in Net Income compared to the prior fiscal year.
- Over the 2014–2025 period, Cartesian Therapeutics, Inc.’s net income has declined by 911.7% (from -$12.88 million to -$130.30 million).
- The most recent figure is from Cartesian Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 9, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: